Search research articles
Contact Us
Filters
Showing results (1-10 of 101) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors
Fabio Conforti, Laura Pala
Expert Opinion on Drug Safety
|
September 1, 2021
The effect of patient sex on the efficacy and safety of anticancer immunotherapy
Laura Pala, Fabio Conforti
Med (New York, N.Y.)
|
June 14, 2025
Point of view: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors
Fabio Conforti, Tommaso De Pas
The Lancet. Oncology
|
March 6, 2020
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy
Laura Pala, Fabio Conforti, Aron Goldhirsch
The New England Journal of Medicine
|
February 19, 2025
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
Fabio Conforti, Chiara Oriecuia, Laura Pala
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2025
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer"
Fabio Conforti, Vincenzo Bagnardi, Isabella Sala
Oncotarget
|
August 23, 2018
Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system
Fabio Conforti, Laura Pala, Aron Goldhirsch
Cancer Cell
|
May 10, 2022
Boosting anticancer immunotherapy through androgen receptor blockade
Laura Pala, Tommaso De Pas, Fabio Conforti
Seminars in Oncology
|
October 3, 2022
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action
Laura Pala, Tommaso De Pas, Fabio Conforti
The Journal of Experimental Medicine
|
February 24, 2023
Macrophages and bone metastasis
Diletta Di Mitri, Fabio Conforti, Alberto Mantovani
Page
of 11
Search research articles
Search
Showing results (1-10 of 101) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors
Fabio Conforti, Laura Pala
Expert Opinion on Drug Safety
|
September 1, 2021
The effect of patient sex on the efficacy and safety of anticancer immunotherapy
Laura Pala, Fabio Conforti
Med (New York, N.Y.)
|
June 14, 2025
Point of view: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors
Fabio Conforti, Tommaso De Pas
The Lancet. Oncology
|
March 6, 2020
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy
Laura Pala, Fabio Conforti, Aron Goldhirsch
The New England Journal of Medicine
|
February 19, 2025
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
Fabio Conforti, Chiara Oriecuia, Laura Pala
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2025
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer"
Fabio Conforti, Vincenzo Bagnardi, Isabella Sala
Oncotarget
|
August 23, 2018
Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system
Fabio Conforti, Laura Pala, Aron Goldhirsch
Cancer Cell
|
May 10, 2022
Boosting anticancer immunotherapy through androgen receptor blockade
Laura Pala, Tommaso De Pas, Fabio Conforti
Seminars in Oncology
|
October 3, 2022
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action
Laura Pala, Tommaso De Pas, Fabio Conforti
The Journal of Experimental Medicine
|
February 24, 2023
Macrophages and bone metastasis
Diletta Di Mitri, Fabio Conforti, Alberto Mantovani
Page
of 11